<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02752126</url>
  </required_header>
  <id_info>
    <org_study_id>PROACTIVE</org_study_id>
    <nct_id>NCT02752126</nct_id>
  </id_info>
  <brief_title>A Randomized Phase III Study of Palliative Radiation of Advanced Central Tumors With Intentional Avoidance of the Esophagus</brief_title>
  <acronym>PROACTIVE</acronym>
  <official_title>A Randomized Phase III Study of Palliative Radiation of Advanced Central Tumors With Intentional Avoidance of the Esophagus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized phase II study of palliative radiation of advanced central lung tumors with&#xD;
      intentional avoidance of the esophagus. Patients will be randomized between standard of care&#xD;
      palliative thoracic radiation and esophageal-sparing intensity-modulated radiation therapy&#xD;
      (ES-IMRT) in a 1:1 ratio. Radiotherapy will be administered as soon as possible following&#xD;
      randomization and subjects will be followed for 1 year after completion of their radiation&#xD;
      therapy. The primary endpoint is esophageal quality of life as measured by the Esophageal&#xD;
      Cancer Subscore (ECS) of the Functional Assessment of Cancer Therapy-Esophagus (FACT-E).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Esophageal Quality of Life</measure>
    <time_frame>2 weeks after completion of radiotherapy</time_frame>
    <description>Esophageal quality of life will be measured by the ECS of the FACT-E, measured at 2 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>6 months after completion of radiotherapy</time_frame>
    <description>Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity Rate Differences</measure>
    <time_frame>6 months after completion of radiotherapy</time_frame>
    <description>Differences in rates of grade 2 or higher toxicity between groups will be tested using the Fisher's Exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>6 months after completion of radiotherapy</time_frame>
    <description>Differences in local/regional progression-free survival will be tested using the stratified log-rank test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Further Systemic Therapy</measure>
    <time_frame>6 months after completion of radiotherapy</time_frame>
    <description>Differences in number of cycles of further systemic therapy will be tested using the student's t-test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-Effectiveness/Utility Analysis</measure>
    <time_frame>6 months after completion of radiotherapy</time_frame>
    <description>European Quality of Life-5 Dimensions (EQ-5D) measurements will be converted into utilities to inform cost-effectiveness/utility analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosimetry Comparison - Gross Tumor Volume (GTV)</measure>
    <time_frame>6 months after completion of radiotherapy</time_frame>
    <description>Dosimetric comparison of GTV will be compared using the student's t-test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosimetry Comparison - Planning Target Volume (PTV)</measure>
    <time_frame>6 months after completion of radiotherapy</time_frame>
    <description>Dosimetric comparison of PTV will be compared using the student's t-test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosimetry Comparison - Pulmonary Metrics</measure>
    <time_frame>6 months after completion of radiotherapy</time_frame>
    <description>Dosimetric comparison of standard pulmonary metrics will be compared using the student's t-test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosimetry Comparison - Esophageal Metrics</measure>
    <time_frame>6 months after completion of radiotherapy</time_frame>
    <description>Dosimetric comparison of standard esophageal metrics will be compared using the student's t-test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Standard Palliative Radiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the standard arm will receive a conventional radiotherapy dose will be either 30 gray (Gy) in 10 fraction or 20Gy in 5 fractions. Patients will be stratified by intended dose prior to randomization. Radiation for patients in the standard arm should adhere to the principles of palliative radiation, with goals of alleviating symptoms or preventing potential complications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esophageal Sparing IMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on the experimental arm will receive esophageal-sparing intensity-modulated radiotherapy, with the same dose(s) as in the standard arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional radiotherapy</intervention_name>
    <description>Patients will receive standard palliative radiation in dose of 30Gy in 10 fractions, or 20Gy in 5 fractions.</description>
    <arm_group_label>Standard Palliative Radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Esophageal-Sparing Intensity-Modulated Radiotherapy</intervention_name>
    <description>Patients will receive esophageal-sparing intensity-modulated radiotherapy, of 30Gy in 10 fractions or 20Gy in 5 fractions.</description>
    <arm_group_label>Esophageal Sparing IMRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Joint Committee on Cancer (AJCC) 7th edition stage IV NSCLC or stage III not&#xD;
             eligible for curative intent treatment&#xD;
&#xD;
          -  Intended to receive palliative radiotherapy to the thorax, to a dose of 30Gy in 10&#xD;
             fractions or 20Gy in 5 fractions. In either treatment arm at least 5cm of the&#xD;
             esophagus should be in the intended treatment field.&#xD;
&#xD;
          -  Willingness and ability to provide informed consent&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-3&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Prior or planned systemic therapy (chemotherapy, immunotherapy, targeted agents) is&#xD;
             permissible at the discretion of the treating medical oncologist, provided that no&#xD;
             systemic treatment is given within 2 weeks prior to RT, concurrent with RT or within a&#xD;
             2-week period post RT.&#xD;
&#xD;
          -  Concurrent palliative RT to other metastatic sites is permissible&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior thoracic RT&#xD;
&#xD;
          -  Serious medical comorbidities precluding RT&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Inability to attend the full course of RT or planned follow-up visits&#xD;
&#xD;
          -  Planned concurrent palliative RT to the stomach and/or liver&#xD;
&#xD;
          -  Congenital abnormalities of the esophagus or severe disorders of the esophagus (e.g.&#xD;
             achalasia)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Clinical Cancer Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand River Regional Cancer Centre/Grand River Hospital</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital/ University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trillium Health Partners - Credit Valley Hospital</name>
      <address>
        <city>Mississauga</city>
        <state>ONT</state>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3H 2R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 22, 2016</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2016</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Alexander Louie</investigator_full_name>
    <investigator_title>Radiation Oncologist</investigator_title>
  </responsible_party>
  <keyword>Esophageal sparing</keyword>
  <keyword>Conventional radiotherapy</keyword>
  <keyword>Palliative radiation</keyword>
  <keyword>Central lung tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

